Corvus Pharmaceuticals (FRA:C17) FCF Yield %: -3.10 (As of Jun. 29, 2026)


FRA:C17 Corvus Pharmaceuticals Inc FRA:C17
32 GF Score
Price €11.27
! 1 Warning Sign
View Full Analysis

What is Corvus Pharmaceuticals FCF Yield %?

Corvus Pharmaceuticals FRA:C17 +1.76% 32 FCF Yield % is -3.10 as of Jun. 29, 2026. GuruFocus rates FRA:C17 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,415 Biotechnology companies, Corvus Pharmaceuticals ranks better than 70.81% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Corvus Pharmaceuticals's Trailing 12-Month Free Cash Flow is €-30.18 Mil, and Market Cap is €998.47 Mil. Therefore, Corvus Pharmaceuticals's FCF Yield % for today is -3.10%.

The historical rank and industry rank for Corvus Pharmaceuticals's FCF Yield % or its related term are showing as below:

FRA:C17' s FCF Yield % Range Over the Past 10 Years
Min: -3.1   Med: 0   Max: 0
Current: -3.1

FRA:C17's FCF Yield % is ranked better than
70.81% of 1415 companies
in the Biotechnology industry
Industry Median: -9.62 vs FRA:C17: -3.10

Corvus Pharmaceuticals's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

Corvus Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Corvus Pharmaceuticals FCF Yield % Related Terms

Corvus Pharmaceuticals FCF Yield % Historical Data

* Premium members only.

The historical data trend for Corvus Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corvus Pharmaceuticals FCF Yield % Chart

Corvus Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -7.36 -6.09

Corvus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.06 -8.54 -7.19 -6.81 -3.80

FRA:C17 vs LXRX, CGEM, WVE: FCF Yield % Comparison

For the Biotechnology subindustry, Corvus Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corvus Pharmaceuticals FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Corvus Pharmaceuticals's FCF Yield % falls into.


FRA:C17
32GF Score
Corvus Pharmaceuticals Inc FRA:C17
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corvus Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Corvus Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-28.158 / 462.37443
=-6.09%

Corvus Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-9.053 * 4 / 953.5806
=-3.80%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -3.10 mean?
Corvus Pharmaceuticals (FRA:C17) has a FCF Yield % of -3.10 as of Jun. 29, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Corvus Pharmaceuticals and its competitors. According to the industry distribution chart, Corvus Pharmaceuticals ranks #413 out of 1415 companies in the Biotechnology industry, placing it in the top 29.2%.
Is Corvus Pharmaceuticals' FCF Yield % too high?
Corvus Pharmaceuticals' current FCF Yield % is -3.10. Based on the distribution chart, Corvus Pharmaceuticals ranks #413 out of 1415 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Corvus Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Corvus Pharmaceuticals' FCF Yield % compare to LXRX and CGEM?
According to the Biotechnology industry distribution chart, Corvus Pharmaceuticals ranks #413 out of 1415 companies for FCF Yield %. This puts Corvus Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Corvus Pharmaceuticals and its competitors. Corvus Pharmaceuticals's current FCF Yield % is -3.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corvus Pharmaceuticals stock overvalued right now?
Corvus Pharmaceuticals (FRA:C17) has a current FCF Yield % of -3.10. The current FCF Yield % is -3.10. Corvus Pharmaceuticals' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Corvus Pharmaceuticals (FRA:C17), the current FCF Yield % is -3.10 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corvus Pharmaceuticals Business Description

Other Exchanges CRVS:USAC17:Germany
Address 901 Gateway Boulevard, Third Floor, South San Francisco, CA, USA, 94080
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
32GF Score

Get the complete analysis for FRA:C17

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.27
Price